DK1141315T3 - Modificerede HIV Env-polypeptider - Google Patents
Modificerede HIV Env-polypeptiderInfo
- Publication number
- DK1141315T3 DK1141315T3 DK99968574T DK99968574T DK1141315T3 DK 1141315 T3 DK1141315 T3 DK 1141315T3 DK 99968574 T DK99968574 T DK 99968574T DK 99968574 T DK99968574 T DK 99968574T DK 1141315 T3 DK1141315 T3 DK 1141315T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv env
- env polypeptides
- modified hiv
- polypeptides
- modified
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11449598P | 1998-12-31 | 1998-12-31 | |
US15667099P | 1999-09-29 | 1999-09-29 | |
PCT/US1999/031272 WO2000039303A2 (en) | 1998-12-31 | 1999-12-30 | Modified hiv env polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1141315T3 true DK1141315T3 (da) | 2008-05-19 |
Family
ID=26812260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99968574T DK1141315T3 (da) | 1998-12-31 | 1999-12-30 | Modificerede HIV Env-polypeptider |
Country Status (12)
Country | Link |
---|---|
US (3) | US6689879B2 (da) |
EP (1) | EP1141315B1 (da) |
JP (1) | JP4776075B2 (da) |
AT (1) | ATE384795T1 (da) |
AU (1) | AU2596600A (da) |
CA (1) | CA2358915C (da) |
CY (1) | CY1107393T1 (da) |
DE (1) | DE69938062T2 (da) |
DK (1) | DK1141315T3 (da) |
ES (1) | ES2299276T3 (da) |
PT (1) | PT1141315E (da) |
WO (1) | WO2000039303A2 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
EP1409694A4 (en) * | 2001-07-05 | 2006-02-08 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
EP1427806A4 (en) * | 2001-08-31 | 2006-04-26 | Chiron Corp | ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF |
MXPA04010919A (es) | 2002-05-07 | 2005-01-25 | Chiron Corp | Complejos e hibridos de envoltura de vih-cd4. |
CA2823937A1 (en) | 2002-10-07 | 2004-04-22 | Novartis Vaccines And Diagnostics, Inc. | Hiv vaccine formulations |
CA2539021A1 (en) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
EP1784513A4 (en) | 2004-06-08 | 2010-01-06 | Novartis Vaccines & Diagnostic | FUSION PROTEINS COMPRISING MINIMUM CD4 MODULES AND METHODS OF USING SAME |
EP2295974A1 (en) | 2004-09-08 | 2011-03-16 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Compositions and methods for the detection of HIV-1/HIV-2 infection |
CA2585672A1 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
CN101146827A (zh) | 2005-02-03 | 2008-03-19 | 诺华疫苗和诊断公司 | Hiv tat-cd4杂合分子及其使用方法 |
EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
CN101591379B (zh) * | 2008-05-27 | 2017-01-18 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗 |
US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
EP2780035A1 (en) | 2011-11-14 | 2014-09-24 | Novartis AG | Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof |
WO2016037154A1 (en) * | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
DE102016122317A1 (de) | 2015-11-24 | 2017-05-24 | Glaxosmithkline Intellectual Property Development Limited | Transientes transfektionsverfahren für retrovirale produktion |
WO2019079337A1 (en) | 2017-10-16 | 2019-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US8785609B1 (en) * | 1984-08-22 | 2014-07-22 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cloning and expression of HTLV-III DNA |
US5032510A (en) | 1984-09-26 | 1991-07-16 | Eli Lilly And Company | Method for expression and secretion in bacillus |
CA1341482C (en) | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
JPS62501263A (ja) | 1984-11-29 | 1987-05-21 | スクリツプス クリニツク アンド リサ−チ フアウンデ−シヨン | 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体 |
AU600658B2 (en) | 1984-12-24 | 1990-08-23 | Genentech Inc. | Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use |
FI861626A (fi) | 1985-04-19 | 1986-10-20 | Hoffmann La Roche | Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids. |
WO1987002775A1 (en) | 1985-10-24 | 1987-05-07 | Southwest Foundation For Biomedical Research | Synthetic peptides and use for diagnosis and vaccination for aids and arc |
EP0242216A1 (en) | 1986-04-16 | 1987-10-21 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III |
JPH01500432A (ja) | 1986-07-21 | 1989-02-16 | サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ | Aidsおよびarcのウィルス原因物質に対して免疫化するための組成物および方法 |
US4861707A (en) | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
IL86832A (en) | 1987-06-22 | 2002-09-12 | Medeva Holdings Bv | A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
WO1989002277A2 (en) | 1987-08-28 | 1989-03-23 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
JPH02501192A (ja) | 1987-09-04 | 1990-04-26 | バイオジェン インコーポレイテッド | 可溶性t4蛋白を製造するためのdna配列、組換dna分子および方法 |
US5879907A (en) | 1987-09-14 | 1999-03-09 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof and method |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
IL87902A0 (en) | 1987-10-08 | 1989-03-31 | Dana Farber Cancer Inst Inc | Soluble human cd4 fragments and applications thereof |
US5712088A (en) | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
US5683864A (en) | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
US5714596A (en) | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
CA1340748C (en) | 1988-07-13 | 1999-09-14 | Stephen Oroszlan | Synthetic hiv protease gene and method for its expression |
ATE112687T1 (de) | 1988-09-13 | 1994-10-15 | Chiron Corp | Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen. |
EP0436634A1 (en) | 1988-10-03 | 1991-07-17 | Repligen Corporation | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids |
CA2003383A1 (en) | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
IL93682A (en) | 1989-03-16 | 1996-06-18 | Yeda Res & Dev | Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them |
WO1990011359A1 (en) | 1989-03-20 | 1990-10-04 | Whitehead Institute For Biomedical Research | Intracellular method of inhibiting hiv in mammalian cells |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
CA2425745C (en) | 1989-03-21 | 2005-03-29 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
WO1990012094A1 (en) | 1989-04-05 | 1990-10-18 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | A clone of double-stranded rna virus and applications thereof |
CA2033175C (en) | 1989-06-01 | 2005-01-11 | Gail P. Mazzara | Self-assembled, defective, non-self-propagating viral particles |
US5130247A (en) | 1989-09-19 | 1992-07-14 | Merck & Co., Inc. | Expression of fusion protein of HIV envelope and HBsAG |
EP0493508A1 (en) | 1989-09-22 | 1992-07-08 | Idec Pharmaceuticals Corporation | Novel peptides associated with the cd4 binding region of gp120 and their methods of use |
DE69019291T2 (de) | 1989-10-23 | 1995-09-21 | F. Hoffmann-La Roche Ag, Basel | Synthetische HTLV-I Hüll-Peptide. |
DE69032484T4 (de) | 1989-10-27 | 1999-09-16 | Arch Development Corp., Chicago | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
AU6965591A (en) | 1989-11-17 | 1991-06-13 | Amgen, Inc. | A method of detecting htlv-i antibodies in human body fluids |
ES2052478T1 (es) | 1989-11-20 | 1994-07-16 | Oncogen | Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos. |
SE468168B (sv) | 1990-02-20 | 1992-11-16 | Replico Medical Ab | Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov |
JP2624894B2 (ja) | 1990-03-09 | 1997-06-25 | カイロン コーポレイション | 天然のコンホメーションを保持している精製gp120組成物 |
US5876724A (en) | 1990-03-19 | 1999-03-02 | Institut Pasteur | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein |
ATE183235T1 (de) | 1990-03-21 | 1999-08-15 | Wolf Hans Joachim Prof Dr | Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon |
DE69111440T2 (de) | 1990-04-03 | 1996-03-28 | Genentech Inc | Methoden und zusammensetzungen zur impfung gegen hiv. |
EP0527789A1 (en) | 1990-04-03 | 1993-02-24 | Genentech, Inc. | Hiv envelope polypeptides |
IL97985A0 (en) | 1990-05-07 | 1992-06-21 | North American Vaccine Inc | Improved vaccine compositions |
AP237A (en) | 1990-05-29 | 1993-04-29 | Cedars Sinai Medical Center | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use. |
WO1991019803A1 (en) | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
SE470074B (sv) | 1990-08-16 | 1993-11-01 | Replico Medical Ab | Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider |
EP0551308A4 (en) | 1990-08-29 | 1994-09-14 | Us Health | Novel peptide antigens and immunoassays, test kits and vaccines using the same |
US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
AU653366B2 (en) | 1990-09-28 | 1994-09-29 | Hospital For Joint Diseases | Method for inhibiting the infectivity of human immunodeficiency virus |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
PT100090A (pt) | 1991-02-04 | 1993-07-30 | Univ Saskatchewan | Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6 |
EP0721340A1 (en) | 1991-03-07 | 1996-07-17 | Seragen, Inc. | Use of cell surface receptor targeted molecules for the treatment of viral diseases |
WO1993002102A1 (en) | 1991-07-23 | 1993-02-04 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Novel peptide antigens and immunoassays, test kits and vaccines using the same |
US5558865A (en) | 1991-08-22 | 1996-09-24 | Nissin Shokuhin Kabushiki Kaisha | HIV immunotherapeutics |
ATE173024T1 (de) | 1991-08-22 | 1998-11-15 | Nissin Food Products Ltd | In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper |
RU2136311C1 (ru) | 1991-09-13 | 1999-09-10 | Чирон Корпорейшн | Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
US5686078A (en) | 1992-09-14 | 1997-11-11 | Connaught Laboratories, Inc. | Primary and secondary immunization with different physio-chemical forms of antigen |
CA2105629A1 (en) | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
JP3658690B2 (ja) | 1993-01-16 | 2005-06-08 | マンフレート シャヴァラー | ウイルスの膜蛋白質の天然ドメインの獲得方法、特にhivに対するワクチンとしてのそれらの使用 |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
WO1994023069A1 (en) | 1993-03-26 | 1994-10-13 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
US5869624A (en) * | 1993-03-26 | 1999-02-09 | Progenics Pharmaceuticals, Inc. | HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
AU700371B2 (en) * | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
CN1111540C (zh) | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | 串联的合成hiv-1肽类 |
US5614413A (en) | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
US5955342A (en) | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5550280A (en) | 1994-11-30 | 1996-08-27 | Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee | Hindered aromatic ester compounds useful as anti-viral agents |
CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
US5741492A (en) | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6087486A (en) | 1996-01-29 | 2000-07-11 | The Trustees Of The University Of Pennsylvania | Nucleotide sequences encoding vpr receptor protein |
US6060587A (en) | 1996-01-29 | 2000-05-09 | The Trustees Of The University Of Pennsylvania | Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle |
US5951975A (en) | 1996-06-28 | 1999-09-14 | University Of Pittsburgh | Induction of CTLs specific for natural antigens by cross priming immunization |
ATE229073T1 (de) | 1996-09-06 | 2002-12-15 | Univ California | Protein e25a, methoden zu dessen herstellung und anwendung |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6139833A (en) | 1997-08-08 | 2000-10-31 | Lexicon Genetics Incorporated | Targeted gene discovery |
US5858675A (en) | 1997-05-13 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Double-stranded RNA-binding protein |
US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
US5932442A (en) | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
JP2002511257A (ja) | 1998-04-14 | 2002-04-16 | カイロン コーポレイション | 目的の遺伝子を発現するための非クローニング技術 |
US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
JP2003513635A (ja) | 1999-11-01 | 2003-04-15 | カイロン コーポレイション | 発現ベクター、トランスフェクション系、およびそれらの使用方法 |
-
1999
- 1999-12-30 DK DK99968574T patent/DK1141315T3/da active
- 1999-12-30 DE DE69938062T patent/DE69938062T2/de not_active Expired - Lifetime
- 1999-12-30 EP EP99968574A patent/EP1141315B1/en not_active Expired - Lifetime
- 1999-12-30 JP JP2000591194A patent/JP4776075B2/ja not_active Expired - Fee Related
- 1999-12-30 AT AT99968574T patent/ATE384795T1/de active
- 1999-12-30 WO PCT/US1999/031272 patent/WO2000039303A2/en active IP Right Grant
- 1999-12-30 US US09/476,242 patent/US6689879B2/en not_active Expired - Fee Related
- 1999-12-30 AU AU25966/00A patent/AU2596600A/en not_active Abandoned
- 1999-12-30 PT PT99968574T patent/PT1141315E/pt unknown
- 1999-12-30 CA CA2358915A patent/CA2358915C/en not_active Expired - Fee Related
- 1999-12-30 ES ES99968574T patent/ES2299276T3/es not_active Expired - Lifetime
-
2003
- 2003-07-25 US US10/452,018 patent/US7662916B2/en not_active Expired - Fee Related
-
2008
- 2008-04-15 CY CY20081100418T patent/CY1107393T1/el unknown
-
2009
- 2009-11-19 US US12/621,992 patent/US20100092502A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CY1107393T1 (el) | 2012-12-19 |
WO2000039303A3 (en) | 2000-09-21 |
US20020146683A1 (en) | 2002-10-10 |
US20090304740A1 (en) | 2009-12-10 |
JP2002533125A (ja) | 2002-10-08 |
EP1141315A2 (en) | 2001-10-10 |
US6689879B2 (en) | 2004-02-10 |
US7662916B2 (en) | 2010-02-16 |
EP1141315B1 (en) | 2008-01-23 |
ES2299276T3 (es) | 2008-05-16 |
WO2000039303A2 (en) | 2000-07-06 |
ATE384795T1 (de) | 2008-02-15 |
CA2358915A1 (en) | 2000-07-06 |
JP4776075B2 (ja) | 2011-09-21 |
DE69938062T2 (de) | 2009-01-15 |
PT1141315E (pt) | 2008-05-05 |
DE69938062D1 (de) | 2008-03-13 |
CA2358915C (en) | 2010-06-01 |
AU2596600A (en) | 2000-07-31 |
US20100092502A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1141315T3 (da) | Modificerede HIV Env-polypeptider | |
MXPA02004666A (es) | Gelatinas recombinantes. | |
HK1145692A1 (zh) | 人血管生成素- 的特異結合劑 | |
FI963070A0 (fi) | Klooripyrimidiinivälituotteita | |
DK1091975T3 (da) | Ny cyclosporin med forbedret aktivitetsprofil | |
DK0912176T3 (da) | Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression | |
TR199802616T2 (xx) | �ift-konveks, h�zl� par�alanan dozaj formlar�. | |
NO963462L (no) | Paramunitetinducer basert på kombinasjoner av poxvirus komponenter, fremgangsmåte for fremstilling derav og anvendelse som medikament | |
DE3775170D1 (de) | Trockenes abziehbild, dessen unerwuenschte flaechen sich selbststaendig von den bildflaechen trennen. | |
DE3772318D1 (de) | Wenigschaeumende, alkalistabile, amphoterische, oberflaechenaktive mittel. | |
DE69003202D1 (de) | Hochfeste, hitzebeständige, niedrig legierte Stähle. | |
WO2004037847A3 (en) | Hiv envelope-cd4 complexes and hybrids | |
DE3766626D1 (de) | Poroese, faserige fluorkohlenstoff-strukturen. | |
PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
DK1037916T3 (da) | Erythrovirus og dets anvendelser | |
TR200001745T2 (tr) | Keton peroksit türevleri, bunların hazırlanması ve kullanılması | |
GT199900062A (es) | Preparados efervescentes. | |
PE20399A1 (es) | Muteina ob | |
ATE309374T1 (de) | Humane carboxypeptidasen und diese kodierende polynukleotide | |
DE60126962D1 (de) | Menschliche phospholipasen und diese kodierende polynukleotide | |
DE69016524D1 (de) | CD4-Fragment mit Anti-HIV-Aktivitäten. | |
DE60119757D1 (de) | Menschliche ionenaustauschproteine und dafür kodierende polynukleotiden | |
FI893211A0 (fi) | Antihypertensiva, n-terminala eteraminodiolamino-syraderivat. | |
IT7827159A0 (it) | Mescolatore, in particolare mescolatore per ferro crudo. | |
PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao |